Presented at #AHA23:
ORBITA-2 trial: In patients with stable angina who were receiving little or no antianginal medication and had documented ischemia, PCI resulted in a better health status with respect to angina than placebo at 12 weeks. Full results: https://t.co/o23lFeHgWA
So excited for the @crfheart Interventional Cardiology Fellows course! Thank you to the organizers.
Started today off with the imaging pre-course... #fellows2023
It was an honor to be a part of the first Long Island Fellows Forum since before the COVID pandemic! Thank you for having me present.
A big thank you to @GiorgioMedranda and @stentdoc1. Looking forward to the next one!
A triumphant return for the #LongIslandFellowsForum!
Thank you to all attendees and to @djkesh2008_t Hymie Chera, Denis Yusupov, @LinleHouMD, @drjeffle and Nicholas J. Beccarino for the terrific presentations!
See you in the fall!
Thank you @DrBillLombardi for the inspiring grand rounds today at @StonyBrookMed! As a current interventional cardiology fellow there was so much to take away from this. I really appreciated your candid discussion about failure, vulnerabilities, and ego.
#CardiacFellows#CardioTwitter: Don't miss this webinar directed by @carlosalviar and hosted by @ZOLLTherOx on Optimizing Care in Today's CICU. Mar 22/24/29 at 5:30 CT/6:30 ET. Register here: https://t.co/WZWKvOdb1s
Breaking news: @US_FDA has approved empagliflozin for the treatment of patients with heart failure with preserved ejection (HFpEF), a cohort that usually has few effective treatment options.
https://t.co/tPpJQaCnlf